{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:00:54Z","timestamp":1785009654723,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Urothelial carcinoma (UC) is a common malignant tumor of the urinary tract, with bladder cancer as the most frequent type. Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC), and perioperative chemotherapy is recommended in addition to RC in guidelines. However, no established evidence defines the optimal regimen and number of cycles, and treatment varies by institution. Therefore, this study aimed to clarify perioperative treatment patterns for MIBC using a hospital-based claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with claims records for bladder cancer recorded during the case-identification window (2012\u20132020) were identified using the Medical Data Vision Co., Ltd. database. The database spans April 2008 to July 2021, enabling longitudinal assessment. Patient characteristics and prescribed perioperative chemotherapy regimens were analyzed. Factors associated with neoadjuvant chemotherapy (NAC) were examined using univariable analysis and an exploratory multivariable logistic regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 6,723 patients, 78.5% were men, with a median diagnosis age of 71 years. The treatment groups included 2,324 patients who received NAC, 598 who received adjuvant chemotherapy (AC), 364 who received NAC and AC, and 3,437 who underwent RC-only. NAC utilization rate increased over time (\n                      <jats:italic>P<\/jats:italic>\n                      for trend\u2009&lt;\u20090.0001). Gemcitabine plus cisplatin was the most frequently administered regimen. Univariable analysis revealed an association between clinical stage 3 or higher and the NAC administration. In contrast, older age and comorbidities were associated with non-administration of NAC. Furthermore, the hospital size and cancer hospital designation influenced NAC administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Perioperative chemotherapy utilization for MIBC has increased annually. Patient characteristics and treatment facility factors influence NAC administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01995-1","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:41:41Z","timestamp":1763970101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database"],"prefix":"10.1186","volume":"25","author":[{"given":"Ayumi","family":"Yamazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-0435","authenticated-orcid":false,"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-613X","authenticated-orcid":false,"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-590X","authenticated-orcid":false,"given":"Keisuke","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4572-1333","authenticated-orcid":false,"given":"Hayato","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-5418","authenticated-orcid":false,"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"TW Flaig","year":"2020","unstructured":"Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:329\u201354. https:\/\/doi.org\/10.6004\/jnccn.2020.0011.","journal-title":"J Natl Compr Canc Netw"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810. https:\/\/doi.org\/10.1016\/S0140-6736(16)30512-8.","journal-title":"Lancet"},{"key":"1995_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031. discussion 475-7.","journal-title":"Eur Urol"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H, et al. Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol. 2020;27:702\u20139. https:\/\/doi.org\/10.1111\/iju.14281.","journal-title":"Int J Urol"},{"key":"1995_CR5","unstructured":"NCCN Clinical Practice. Guideline in Oncology (NCCN Guidelines\u00ae) Version 4.2019-July 10, 2019."},{"key":"1995_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"key":"1995_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"key":"1995_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"International Collaboration of Trialists","year":"2011","unstructured":"International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.32.3139.","journal-title":"J Clin Oncol"},{"key":"1995_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:189\u2013201. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.005.","journal-title":"Eur Urol"},{"key":"1995_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.033.","journal-title":"Eur Urol"},{"key":"1995_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/jjco\/hyw005","volume":"46","author":"T Koie","year":"2016","unstructured":"Koie T, Ohyama C, Fujimoto H, et al. Diversity in treatment modalities of stage II\/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol. 2016;46:468\u201374. https:\/\/doi.org\/10.1093\/jjco\/hyw005.","journal-title":"Jpn J Clin Oncol"},{"key":"1995_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical data vision and Japanese medical data center. Drugs Real World Outcomes. 2022;9:175\u201387. https:\/\/doi.org\/10.1007\/s40801-022-00296-5.","journal-title":"Drugs Real World Outcomes"},{"key":"1995_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"key":"1995_CR15","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/cncr.30907","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123:4346\u201355. https:\/\/doi.org\/10.1002\/cncr.30907.","journal-title":"Cancer"},{"key":"1995_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky MD, Stensland KD, Moshier E, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol. 2016;34:825\u201332. https:\/\/doi.org\/10.1200\/JCO.2015.64.1076.","journal-title":"J Clin Oncol"},{"key":"1995_CR17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927\u201334. https:\/\/doi.org\/10.1016\/s0140-6736(03)13580-5.","journal-title":"Lancet"},{"key":"1995_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006.","journal-title":"Eur Urol"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.2217\/fon-2019-0434","volume":"15","author":"P Grivas","year":"2019","unstructured":"Grivas P, DerSarkissian M, Shenolikar R, Lalibert\u00e9 F, Doleh Y, Duh MS. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. Future Oncol. 2019;15:3809\u201318. https:\/\/doi.org\/10.2217\/fon-2019-0434.","journal-title":"Future Oncol"},{"key":"1995_CR20","unstructured":"National Cancer Center, Japan. (2014\u20132015) Cancer Information Service, Cancer Survival in Hospital-based Cancer Registries [in Japanese]. https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_reg_surv\/pdf\/hosp_c_reg_surv_all_2014-2015.pdf. Accessed 15 Dec 2024."},{"key":"1995_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/iju.13141","volume":"23","author":"Y Kubota","year":"2016","unstructured":"Kubota Y, Nakaigawa N, Nishiyama H, et al. Essential content of evidence-based clinical practice guidelines for bladder cancer: the Japanese urological association 2015 update. Int J Urol. 2016;23:640\u20135. https:\/\/doi.org\/10.1111\/iju.13141.","journal-title":"Int J Urol"},{"key":"1995_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1442-2042.2010.02486.x","volume":"17","author":"Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer and the Japanese Urological Association","year":"2010","unstructured":"Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer and the Japanese Urological Association. Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition). Int J Urol. 2010;17:102\u201324. https:\/\/doi.org\/10.1111\/j.1442-2042.2010.02486.x.","journal-title":"Int J Urol"},{"key":"1995_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.21037\/tau.2017.09.12","volume":"6","author":"B Prad\u00e8re","year":"2017","unstructured":"Prad\u00e8re B, Thibault C, Vetterlein MW, et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. Transl Androl Urol. 2017;6:1049\u201359. https:\/\/doi.org\/10.21037\/tau.2017.09.12.","journal-title":"Transl Androl Urol"},{"key":"1995_CR24","volume-title":"Clinical practice guideline for bladder cancer 2019 edition [expanded edition]","author":"Japanese Urological Association, editor","year":"2023","unstructured":"Japanese Urological Association, editor. Clinical practice guideline for bladder cancer 2019 edition [expanded edition]. Tokyo: Igakutosho-shuppan Ltd; 2023."},{"key":"1995_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol. 2022;81:50\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.028.","journal-title":"Eur Urol"},{"key":"1995_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ecc.12282","volume":"24","author":"C Chau","year":"2015","unstructured":"Chau C, Wheater M, Geldart T, Crabb SJ. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. Eur J Cancer Care (Engl). 2015;24:155\u201362. https:\/\/doi.org\/10.1111\/ecc.12282.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1995_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/annonc\/mdi039","volume":"16","author":"A Bamias","year":"2005","unstructured":"Bamias A, Efstathiou E, Moulopoulos LA, et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol. 2005;16:307\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdi039.","journal-title":"Ann Oncol"},{"key":"1995_CR28","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.2005.04.3091","volume":"24","author":"GV Raj","year":"2006","unstructured":"Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24:3095\u2013100. https:\/\/doi.org\/10.1200\/JCO.2005.04.3091.","journal-title":"J Clin Oncol"},{"key":"1995_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571.","journal-title":"J Clin Oncol"},{"key":"1995_CR30","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433.","journal-title":"J Clin Oncol"},{"key":"1995_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcsup.2016.01.001","volume":"14","author":"J Bellmunt","year":"2016","unstructured":"Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer Supplements. 2016;14:1\u201320. https:\/\/doi.org\/10.1016\/j.ejcsup.2016.01.001.","journal-title":"European Journal of Cancer Supplements"},{"key":"1995_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4111\/icu.20200132","volume":"61","author":"C McFerrin","year":"2020","unstructured":"McFerrin C, Davaro F, May A, Raza S, Siddiqui S, Hamilton Z. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer. Investig Clin Urol. 2020;61:565\u201372. https:\/\/doi.org\/10.4111\/icu.20200132.","journal-title":"Investig Clin Urol"},{"key":"1995_CR33","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00345-018-2371-y","volume":"36","author":"SA Fletcher","year":"2018","unstructured":"Fletcher SA, Harmouch SS, Krimphove MJ, et al. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018;36:1767\u201374. https:\/\/doi.org\/10.1007\/s00345-018-2371-y.","journal-title":"World J Urol"},{"key":"1995_CR34","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/ijc.31833","volume":"144","author":"TJN Hermans","year":"2019","unstructured":"Hermans TJN, Voskuilen CS, Deelen M, et al. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Int J Cancer. 2019;144:1453\u20139. https:\/\/doi.org\/10.1002\/ijc.31833.","journal-title":"Int J Cancer"},{"key":"1995_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.urology.2013.07.072","volume":"83","author":"HB Zaid","year":"2014","unstructured":"Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National cancer database. Urology. 2014;83:75\u201380. https:\/\/doi.org\/10.1016\/j.urology.2013.07.072.","journal-title":"Urology"},{"key":"1995_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2015.11.006","volume":"54","author":"TJN Hermans","year":"2016","unstructured":"Hermans TJN, van de Fransen Putte EE, Horenblas S, et al. Perioperative treatment and radical cystectomy for bladder cancer\u2013a population based trend analysis of 10,338 patients in the Netherlands. Eur J Cancer. 2016;54:18\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.006.","journal-title":"Eur J Cancer"},{"key":"1995_CR37","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1002\/cam4.2449","volume":"8","author":"S Karim","year":"2019","unstructured":"Karim S, Mackillop WJ, Brennan K, et al. Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. Cancer Med. 2019;8:6258\u201371. https:\/\/doi.org\/10.1002\/cam4.2449.","journal-title":"Cancer Med"},{"key":"1995_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bju.16611","volume":"135","author":"J Bosveld","year":"2025","unstructured":"Bosveld J, Nguyen TQ, Boormans JL, et al. The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study. BJU Int. 2025;135:766\u201374. https:\/\/doi.org\/10.1111\/bju.16611.","journal-title":"BJU Int"},{"key":"1995_CR39","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1007\/s00345-021-03776-5","volume":"39","author":"F Claps","year":"2021","unstructured":"Claps F, van de Kamp MW, Mayr R, et al. Risk factors associated with positive surgical margins\u2019 location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39:4363\u201371. https:\/\/doi.org\/10.1007\/s00345-021-03776-5.","journal-title":"World J Urol"},{"key":"1995_CR40","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068.","journal-title":"J Clin Oncol"},{"key":"1995_CR41","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.07.757.","journal-title":"J Clin Oncol"},{"key":"1995_CR42","unstructured":"Pharmaceuticals and Medical Devices Agency. (2008). Review report for Gemzar Injection [in Japanese]. https:\/\/www.pmda.go.jp\/drugs\/2008\/P200800069\/530471000_21300AMY00404000_A100_1.pdf. Accessed 15 Dec 2024."},{"key":"1995_CR43","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.29387","volume":"121","author":"MD Galsky","year":"2015","unstructured":"Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121:2586\u201393. https:\/\/doi.org\/10.1002\/cncr.29387.","journal-title":"Cancer"},{"key":"1995_CR44","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.urology.2011.10.050","volume":"79","author":"O Yeshchina","year":"2012","unstructured":"Yeshchina O, Badalato GM, Wosnitzer MS, et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012;79:384\u201390. https:\/\/doi.org\/10.1016\/j.urology.2011.10.050.","journal-title":"Urology"},{"key":"1995_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/jjco\/hyy122","volume":"48","author":"K Okabe","year":"2018","unstructured":"Okabe K, Shindo T, Maehana T, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. Jpn J Clin Oncol. 2018;48:934\u201341. https:\/\/doi.org\/10.1093\/jjco\/hyy122.","journal-title":"Jpn J Clin Oncol"},{"key":"1995_CR46","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1574\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30541-6.","journal-title":"Lancet Oncol"},{"key":"1995_CR47","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00345-022-04160-7","volume":"40","author":"SMH Einerhand","year":"2022","unstructured":"Einerhand SMH, Black AJ, Zargar H, et al. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2022;40:2707\u201315. https:\/\/doi.org\/10.1007\/s00345-022-04160-7.","journal-title":"World J Urol"},{"key":"1995_CR48","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1097\/JU.0000000000002062.11","volume":"206","author":"E Blanco-Martinez","year":"2021","unstructured":"Blanco-Martinez E, Patel HD, Patel SH, et al. Deviations in cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer and implications for pathologic response and survival. J Urol. 2021;206:e764\u20135. https:\/\/doi.org\/10.1097\/JU.0000000000002062.11.","journal-title":"J Urol"},{"key":"1995_CR49","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/pds.5263","volume":"30","author":"C de Luise","year":"2021","unstructured":"de Luise C, Sugiyama N, Morishima T, et al. Validity of claims-based algorithms for selected cancers in Japan: results from the VALIDATE-J study. Pharmacoepidemiol Drug Saf. 2021;30:1153\u201361. https:\/\/doi.org\/10.1002\/pds.5263.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1995_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bju.15984","volume":"132","author":"F Claps","year":"2023","unstructured":"Claps F, van de Kamp MW, Mayr R, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023;132(2):170\u201380. https:\/\/doi.org\/10.1111\/bju.15984.","journal-title":"BJU Int"},{"key":"1995_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/tau.2016.06.13","volume":"5","author":"Y Klaile","year":"2016","unstructured":"Klaile Y, Schlack K, Boegemann M, et al. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol. 2016;5:692\u2013701. https:\/\/doi.org\/10.21037\/tau.2016.06.13.","journal-title":"Transl Androl Urol"},{"key":"1995_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.euf.2020.04.011","volume":"6","author":"S Daneshmand","year":"2020","unstructured":"Daneshmand S, Nazemi A. Neoadjuvant chemotherapy in variant histology bladder cancer: current evidence. Eur Urol Focus. 2020;6:639\u201341. https:\/\/doi.org\/10.1016\/j.euf.2020.04.011.","journal-title":"Eur Urol Focus"},{"key":"1995_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154349","volume":"13","author":"F Claps","year":"2024","unstructured":"Claps F, Biasatti A, Di Gianfrancesco L, et al. The prognostic significance of histological subtypes in patients with muscle-invasive bladder cancer: an overview of the current literature. J Clin Med. 2024;13:4349. https:\/\/doi.org\/10.3390\/jcm13154349.","journal-title":"J Clin Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01995-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:47:50Z","timestamp":1781617670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01995-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01995-1","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Keio University Faculty of Pharmacy approved this study (Approval No.: 240313\u20133).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study used anonymized database records; therefore, individual participant consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}